InsidersTradesSigma
Follow the DENTSPLY SIRONA Inc. share price and the full insider trade history of the company, a listed issuer based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, DENTSPLY SIRONA Inc. has published 520 insider filings. Market capitalisation: €2.3bn. The latest transaction was reported on 12 August 2026 (Attribution). Among the most active insiders: LUCIER GREGORY T. Every trade is free.
520
Insider Decl.
n/a
Thresholds
€3m
21 ops.
Buy Volume
€3m
5 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate DENTSPLY SIRONA Inc. Hold (neutral), based on 16 analysts. Average price target: US$13.72.
34Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,269 of 29,062 companies
33.3
score / 100
Value37
Quality30
FCF yld4.7%
Earn yld-27%
EV/EBITDA·
ROE-33%
Gross mgn50%
Net mgn-16%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 12 August 2026
Declarations520 total
24,014 shares0Common StockSEC:0000818479-26-000268:0
802 shares@ US$12.120.0004% mcap12.3% of flowCommon StockSEC:0000818479-26-000266:0
6,500 sharesCommon StockSEC:0000818479-26-000214:0
Canonical exit: 13 Sept 2026 (T+90)
15,175 sharesCommon StockSEC:0000818479-26-000208:0
Canonical exit: 9 Sept 2026 (T+90)
10,086 sharesCommon StockSEC:0000818479-26-000209:0
Canonical exit: 9 Sept 2026 (T+90)
10,000 sharesCommon StockSEC:0000818479-26-000210:0
9,985.022 sharesCommon StockSEC:0000818479-26-000211:0
Canonical exit: 13 Sept 2026 (T+90)
10,000 sharesCommon StockSEC:0000818479-26-000212:0
Canonical exit: 10 Sept 2026 (T+90)
22,822 shares0Common StockSEC:0000818479-26-000183:0
28,887 shares0Common StockSEC:0000818479-26-000184:0
22,822 shares0Common StockSEC:0000818479-26-000185:0
22,822 shares0Common StockSEC:0000818479-26-000186:0
22,822 shares0Common StockSEC:0000818479-26-000187:0
22,822 shares0Common StockSEC:0000818479-26-000188:0
28,887 shares0Common StockSEC:0000818479-26-000189:0
22,822 shares0Common StockSEC:0000818479-26-000190:0
22,822 shares0Common StockSEC:0000818479-26-000191:0
22,822 shares0Common StockSEC:0000818479-26-000192:0
38,382 shares0Common StockSEC:0000818479-26-000193:0
38,382 shares0Common StockSEC:0000818479-26-000193:1
38,382 shares0Common StockSEC:0000818479-26-000193:2
15,000 shares@ US$12.4456.8% of flowCommon StockSEC:0000818479-26-000107:0
Canonical exit: 7 Jun 2026 (T+90)
5,000 shares@ US$12.4848.5% of flowCommon StockSEC:0000818479-26-000106:0
Canonical exit: 7 Jun 2026 (T+90)
13,690 shares0Common StockSEC:0000818479-26-000104:0
59,524 shares0Common StockSEC:0000818479-26-000102:0
25 of 520 declarations
关于 DENTSPLY SIRONA Inc.
DENTSPLY SIRONA Inc.（股票代码：XRAY）是一家在美国纳斯达克上市的牙科技术和耗材公司。对于投资者而言，它处于医疗保健、医疗设备和牙科工作流程技术的交汇点，既涉及经常性耗材，也涉及资本密集型设备和数字成像系统。公司全球总部位于北卡罗来纳州夏洛特，对于关注美国医疗保健股的欧洲投资者而言，这是一个相关细节。（[investor.dentsplysirona.com](https://investor.dentsplysirona.com/news-releases/news-release-details/dentsply-sirona-reports-fourth-quarter-and-full-year-2024/?utm_source=openai)） 公司的历史反映了两家成熟牙科业务的结合：DENTSPLY（其历史可追溯到 19 世纪末）和 Sirona（一家德国牙科设备和成像专家）。它们的合并创建了一个更广泛的平台，涵盖牙科生态系统的耗材、设备和软件层面。Dentsply Sirona 强调其国际足迹，产品分销到 150 多个国家，这使其拥有广泛的市场覆盖范围，但也使其面临外汇、区域需求周期和竞争强度的风险。（[fintel.io](https://fintel.io/doc/sec-dentsply-sirona-inc-818479-10k-2024-february-29-19782-244?utm_source=openai)） 在运营方面，该集团提供多元化的产品组合，涵盖修复牙科、牙髓病学、种植体和修复体、正畸、成像和诊断、牙科椅旁设备以及互联数字工作流程解决方案。其竞争地位建立在产品范围广度、长期品牌认知度、已安装基础关系以及将硬件、耗材和软件捆绑到集成临床工作流程中的能力之上。从战略上讲，这很重要，因为牙科越来越受到数字工具、3D 成像和注重效率的实践管理的影响。（[investor.dentsplysirona.com](https://investor.dentsplysirona.com/static-files/0d4ca110-18df-4dcc-85d4-ca53822531c8?utm_source=openai)） Dentsply Sirona 仍然是一家全球性企业，在北美、欧洲和其他国际市场拥有重要的业务。2024 年，公司雇佣了大约 4,600 名员工，并继续优化其地理足迹以提高效率。对于投资者而言，这意味着一个具有全球多元化的成熟运营基础，但也需要在增长较慢的终端市场中进行严谨的执行。（[investor.dentsplysirona.com](https://investor.dentsplysirona.com/static-files/0d4ca110-18df-4dcc-85d4-ca53822531c8?utm_source=openai)） 近期发展至关重要。2024 财年包括与正畸、种植体和互联技术相关的重大非现金减值费用，反映了某些类别的需求疲软和竞争压力。在 2025 年和 2026 年，公司经历了显著的领导层变动：Dan Scavilla 被任命为首席执行官，Matt Garth 成为首席财务官，公司启动了“重回增长”行动计划，旨在加强商业执行、改善客户体验和优化资本配置。2025 年 10 月，Dentsply Sirona 还披露，2022 年 5 月启动的 SEC 调查已结束，SEC 不打算采取执法行动。（[investor.dentsplysirona.com](https://investor.dentsplysirona.com/news-releases/news-release-details/dentsply-sirona-reports-fourth-quarter-and-full-year-2024/?utm_source=openai)）
